Literature DB >> 2378844

Changes in height of choroidal melanomas after plaque therapy.

D H Abramson1, C A Servodidio, B McCormick, D Fass, E Zang.   

Abstract

Serial ultrasonic measurements of 82 uveal melanomas treated with brachytherapy plaques (cobalt-60 and iodine-125) and followed up for up to 141 months revealed that no two patients had identical patterns of change. The mean absolute change in tumour height after treatment was 1.8 mm at six months, 5.6 mm at 48 months for large tumours, and 0.9 and 1.9 mm for medium sized tumours. Eighty of the 82 patients fell into one of three patterns of response: 57 patients had a decrease in height after treatment (type D), 13 patients had the same height after treatment (type S), and 10 patients had a progressive increase in height (type I). Life table comparison showed no correlation between survival and location of tumour, sex of patient, size of tumour when treated, or laterality. There was a slight correlation between age and survival. Patients older than 60 died more frequently from metastatic melanoma than those under 60 (p = 0.06). Life table analysis showed a significant correlation between tumour regression type and survival. At 48 months the best cumulative probability of survival was in patients with type D (88% alive) compared with those of type I (34% alive, p = 0.0004).

Entities:  

Mesh:

Year:  1990        PMID: 2378844      PMCID: PMC1042128          DOI: 10.1136/bjo.74.6.359

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  8 in total

1.  The use and abuse of cobalt plaques in the treatment of choroidal malignant melanomata.

Authors:  M A Bedford
Journal:  Trans Ophthalmol Soc U K       Date:  1973

2.  Conservative treatment of intraocular melanomas.

Authors:  R S Long; M A Galin; M Rotman
Journal:  Trans Am Acad Ophthalmol Otolaryngol       Date:  1971 Jan-Feb

3.  Radiotherapy for malignant melanoma of the choroid.

Authors:  H B Stallard
Journal:  Br J Ophthalmol       Date:  1966-03       Impact factor: 4.638

4.  Post-irradiation regression of choroidal melanomas as a risk factor for death from metastatic disease.

Authors:  J J Augsburger; J W Gamel; J A Shields; A M Markoe; L W Brady
Journal:  Ophthalmology       Date:  1987-09       Impact factor: 12.079

5.  Cobalt plaque therapy of posterior uveal melanomas.

Authors:  J A Shields; J J Augsburger; L W Brady; J L Day
Journal:  Ophthalmology       Date:  1982-10       Impact factor: 12.079

6.  Regression of uveal malignant melanomas following cobalt-60 plaque. Correlates between acoustic spectrum analysis and tumor regression.

Authors:  D J Coleman; F L Lizzi; R H Silverman; R M Ellsworth; B G Haik; D H Abramson; M E Smith; M J Rondeau
Journal:  Retina       Date:  1985 Spring-Summer       Impact factor: 4.256

7.  Regression of posterior uveal melanomas following cobalt-60 plaque radiotherapy.

Authors:  A F Cruess; J J Augsburger; J A Shields; L W Brady; A M Markoe; J L Day
Journal:  Ophthalmology       Date:  1984-12       Impact factor: 12.079

8.  Regression of posterior uveal malignant melanomas after cobalt plaque radiotherapy.

Authors:  J J Augsburger; B T McNeary; H von Below; J W Gamel; J A Shields; L W Brady; A M Markoe; J L Day
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1986       Impact factor: 3.117

  8 in total
  10 in total

1.  A randomized, controlled trial of varying radiation doses in the treatment of choroidal melanoma.

Authors:  E S Gragoudas
Journal:  Trans Am Ophthalmol Soc       Date:  1998

2.  Risk factors for metastatic uveal melanoma after trans-scleral local resection.

Authors:  B E Damato; J Paul; W S Foulds
Journal:  Br J Ophthalmol       Date:  1996-02       Impact factor: 4.638

3.  Combined plaque radiotherapy and transpupillary thermotherapy in choroidal melanoma: 5 years' experience.

Authors:  Y M Bartlema; J A Oosterhuis; J G Journée-De Korver; R E Tjho-Heslinga; J E E Keunen
Journal:  Br J Ophthalmol       Date:  2003-11       Impact factor: 4.638

4.  Regression patterns of choroidal melanoma: After palladium-103 (103Pd) plaque brachytherapy.

Authors:  Abhilasha Maheshwari; Paul T Finger
Journal:  Eur J Ophthalmol       Date:  2018-05-22       Impact factor: 2.597

5.  Regression patterns of uveal melanoma after iodine-125 plaque brachytherapy.

Authors:  Rui Fang; Heng Wang; Yang Li; Yue-Ming Liu; Wen-Bin Wei
Journal:  BMC Ophthalmol       Date:  2021-03-16       Impact factor: 2.209

6.  Regression of posterior uveal melanoma following iodine-125 plaque radiotherapy based on pre-treatment tumor apical height.

Authors:  David Miguel; María Antonia Saornil; Jesús María de Frutos; Ciro García-Álvarez; Pilar Alonso; Patricia Diezhandino
Journal:  J Contemp Brachytherapy       Date:  2021-04-14

7.  Radiological and clinical findings in uveal melanoma treated by plaque interventional radiotherapy (brachytherapy): Visual atlas and literature review on response assessment.

Authors:  Bruno Fionda; Monica Maria Pagliara; Valentina Lancellotta; Carmela Grazia Caputo; Calogero Casà; Maria Grazia Sammarco; Elisa Placidi; Patrizia Cornacchione; Francesco Boselli; Roberto Iezzi; Cesare Colosimo; Luca Tagliaferri; Maria Antonietta Blasi
Journal:  J Contemp Brachytherapy       Date:  2022-02-04

8.  Intravitreal bevacizumab combined with plaque brachytherapy reduces melanoma tumor volume and enhances resolution of exudative detachment.

Authors:  Samuel K Houston; Nisha V Shah; Christina Decatur; Marcela Lonngi; William Feuer; Arnold M Markoe; Timothy G Murray
Journal:  Clin Ophthalmol       Date:  2013-01-22

9.  Ultrasound Biomicroscopy Documented Anterior Uveal Melanoma Regression after Ruthenium-106 Plaque Therapy.

Authors:  Biljana Kuzmanović Elabjer; Mladen Bušić; Andrej Pleše; Mirjana Bjeloš; Daliborka Miletić; Nenad Vukojević
Journal:  Ocul Oncol Pathol       Date:  2021-02-15

10.  Comparison of Iodide-125 and Ruthenium-106 Brachytherapy in the Treatment of Choroidal Melanomas.

Authors:  Fariba Ghassemi; Shahab Sheibani; Mojtaba Arjmand; Hosein Poorbaygi; Emad Kouhestani; Siamak Sabour; Farhad Samiei; Akbar Beiki-Ardakani; Mahmood Jabarvand; Ali Sadeghi Tari
Journal:  Clin Ophthalmol       Date:  2020-02-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.